Lack of association between plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy of prematurity in premature neonates
- Lack of association between plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy of ...
2 Trabzon Kanuni Education and Research Hospital, Genetic Diseases Diagnosis Center, Trabzon, Turkey
3 Department of Medical Genetics, İstanbul Medeniyet University, Faculty of Medicine, İstanbul, Turkey
4 Department of Pediatrics, Neonatology Unit, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey
5 Ankara University Biotechnology Institute, Besevler, Ankara, Turkey
Background and aims: Retinopathy of prematurity (ROP) is a proliferative vascular disorder in premature neonates. Due to differences in individual responses to the treatment, various genetic factors have been investigated in the etiologyof ROP. We investigated the gene polymorphism of plasminogen activator inhibitor(PAI-1) 4G/5 as a risk factor of ROP development. Materials and Methods: 73 neonates with ROP and 101 controls were enrolled to study. Genotyping was analyzedusing real time PCR. Results: The proportion of 4G/4G, 4G/5G and 5G/5G genotypesdid not differ statistically between the ROP and control groups (p>0.05). Having PAI-14G/4G genotype polymorphism seems to develop the risk of ROP (OR =0.702; 95%CI: 0.300-1.639) less than PAI-1 4G/5G polymorphisms (OR =1.064; 95% CI: 0.469-2.410). 4G/4G genotype frequency was decreasing as the stages of ROP were increasing though there was no statistically signifiant difference between proportion of genotypes and ROP stages. Conclusion: This study showed that PAI-1 4G/5G genotypewhich is known as a risk factor for angiogenesis is not a predisposing factor for ROPdevelopment.